

18th January, 2025

To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001

To,  
The Manager – Listing,  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: GLS

Dear Sir/Madam,

**Sub: Glenmark Life Sciences rebrands as Alivus Life Sciences**

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

**For Alivus Life Sciences Limited**  
(Formerly known as Glenmark Life Sciences Limited)

**Rudalf Corriea**  
**Company Secretary and Compliance Officer**  
*Encl: As above*

**Alivus Life Sciences Limited** (formerly Glenmark Life Sciences Limited)

**Corporate Office:**

4th Floor, OIA House, 470, Cardinal Gracious Road  
Andheri (E), Mumbai 400 099, Maharashtra, India

**Registered Office:**

Plot No 170-172, Chandramouli Industrial Estate  
Mohol Bazarpeth, Solapur 413 213, India

T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: [complianceofficer@glenmarklifesciences.com](mailto:complianceofficer@glenmarklifesciences.com) | W: [www.alivus.com](http://www.alivus.com)



Press Note

## Glenmark Life Sciences rebrands as Alivus Life Sciences

**Mumbai, January 18, 2025:** Glenmark Life Sciences, a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas, announces its change of identity to Alivus Life Sciences, marking an exciting new chapter in its journey. This is consequent to the acquisition by Nirma Limited, a diversified conglomerate with interest in consumer products, chemicals, and pharmaceuticals.

The change is reflective of the company's evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space. The new identity, Alivus Life Sciences, represents vitality and growth with a renewed focus. It embodies the optimism and transformation the company is embracing as it enters the next phase of its journey.

### Key Changes

**Corporate Identity:** Alivus Life Sciences Limited (Formerly Glenmark Life Sciences Limited)

### **Stock Exchange Scrip**

**On NSE:** ALIVUS (NSE symbol changes from 'GLS' to 'ALIVUS', effective January 20, 2025)

**On BSE:** 543322 (BSE Code remains the same)

**Website:** The official website is now [alivus.com](https://alivus.com), providing comprehensive information about the company's updated brand identity, services and initiatives.

This rebranding to Alivus Life Sciences marks an important milestone in the company's journey. It symbolizes our commitment to enhancing services for our customers, stakeholders, and employees. While the company's name has changed, its dedication to quality and innovation remains steadfast.

**Alivus Life Sciences Limited** (formerly Glenmark Life Sciences Limited)

**Corporate Office:**

4th Floor, OIA House, 470, Cardinal Gracious Road  
Andheri (E), Mumbai 400 099, Maharashtra, India

**Registered Office:**

Plot No 170-172, Chandramouli Industrial Estate  
Mohol Bazarpeth, Solapur 413 213, India

T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: [complianceofficer@glenmarklifesciences.com](mailto:complianceofficer@glenmarklifesciences.com) | W: [www.alivus.com](https://www.alivus.com)





### **About Alivus Life Sciences Ltd (ALIVUS)**

Alivus Life Sciences Limited (BSE: 543322, NSE: ALIVUS), is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. The company is increasingly providing CDMO services to a range of multinational and specialty pharmaceutical companies. It has a diversified portfolio of 161 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW). The company's 4 manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of 1,424 KL, which are regularly inspected by global regulators such as USFDA, PMDA (Japan) and EDQM (Europe). Alivus Life Sciences is listed on BSE and NSE.

Learn more about Alivus Life Sciences Limited on [www.alivus.com](http://www.alivus.com).

#### **For any further queries please contact:**

Soumi Rao | Senior General Manager – Corporate Communications

Email: [Soumi.Rao@glenmarklifesciences.com](mailto:Soumi.Rao@glenmarklifesciences.com)

Mobile: 9870196931

Ernst & Young LLP – Investor Relations

Diwakar Pingle

Email: [Diwakar.Pingle@in.ey.com](mailto:Diwakar.Pingle@in.ey.com)

Runjhun Jain

Email: [Runjhun.Jain1@in.ey.com](mailto:Runjhun.Jain1@in.ey.com)

